



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Summary of Main Points from the Meeting held on Monday 23rd September 2019

2. Minutes and Summary Notes from last meeting

The minutes and summary notes of the Medicines Group Meeting held on 22nd July 2019 were approved. The summary notes will be disseminated and published on the Trust intranet.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

Nil

Ex-panel

Nil

Removals

Nil

NICE Approved drug applications

- **Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma - NICE TA562**

Approved by NICE February 2019.

Decision: Approved for addition to the formulary

- **Risankizumab for treating moderate to severe plaque psoriasis - NICE TA596**

Approved by NICE August 2019. This was Fast Tracked by NICE therefore approved for addition to the formulary by Chair's action on 20th September 2019.

Decision: Noted

Pharmacoeconomic Board requests

- **Sodium valproate 500mg/5ml "Special" Liquid for uncontrolled epilepsy**

Approved by the Pharmacoeconomic Board on 27/07/2019

For noting by the Group.

Decision: Noted

- **IVIg - Measles Encephalitis (Grey Indication)**

Approved by the Pharmacoeconomic Board on 08/08/2019.

For noting by the Group

Decision: Noted

- **Infliximab - Crohn's Disease**

Approved by the Pharmacoeconomic Board on 02/09/2019.

For noting by the Group.

Decision: Noted



4.2 Trust Medicines Policy

- **Updates to Adult IV Administration Guide**

Fosfomycin

Following Alert Added:

High osmolality: Risk of phlebitis particularly after repeated doses. Use central line where possible if continued use.

Calcuim Gluconate

Slight difference in generics so following details has been added:

2.2 mmol Calcium (950mg calcium gluconate mono-hydrate) in 10mL amp. (Hameln brand)

2.23 mmol/10ml (Kent/ Athlone Labs)

2.25 mmol/10mL (B.Braun brand)

Decision: Approved

4.3 Medicines Optimisation

Nil

4.4 NICE Technical Appraisals and Guidance

a) NICE Technical Appraisals

4 Appraisals published in July 2019

7 Appraisals published in August 2019

TA588 - Nusinersen for treating spinal muscular atrophy

Formulary status / Action

Nil action - Not applicable - CWFT not commissioned

TA589 - Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity

Formulary status / Action

Nil action - Not applicable - CWFT not commissioned

TA590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis

Formulary status / Action

Currently included on the formulary for other indication.

Numbers likely to treat at CWH site: 2 patients per year

Numbers likely to treat at WMUH site: N/A - No ophthalmology Service at WMUH

TA591 - Letermovir for preventing cytomegalovirus disease after a stem cell transplant

Formulary status / Action

Nil action - Not applicable - CWFT not commissioned

TA592 - Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma

Formulary status / Action

Nil action - CWFT currently not commissioned. To challenge this decision re with NHS England. To add to formulary in meantime following receipt of a signed application form from the CW Oncology Team.

TA593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

Formulary status / Action



Currently included on the formulary.

Numbers likely to treat at CWH site: 0 patients per year - Condition not treated at CWH Site

Numbers likely to treat at WMUH site: 10 patients per year

TA594 - Brentuximab vedotin for untreated advanced Hodgkin lymphoma (Terminated Appraisal)

Formulary status / Action

Nil action - Terminated Appraisal

TA595 - Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer

Formulary status / Action

Add to the formulary following receipt of a signed application form from the CW Oncology Team.

TA596 - Risankizumab for treating moderate to severe plaque psoriasis

Formulary status / Action

Added to the formulary following receipt of a signed application form from the Dermatology Team -
See Section 4.1

TA597 - Dapagliflozin with insulin for treating Type 1 Diabetes

Formulary status / Action

Currently included on the formulary.

Numbers likely to treat at CWH site: Will be prescribed - Difficult to estimate numbers likely to treat.

Numbers likely to treat at WMUH site: 0 patients per year.

TA598 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

Formulary status / Action

Nil action - Not applicable - CWFT not commissioned

b) NICE Highly Specialised Technologies published since last meeting

1 Highly Specialised Technologies published in August 2019

HST10 - Patisiran for treating hereditary transthyretin amyloidosis

Formulary status / Action

Nil action - Not applicable - CWFT not commissioned

4.5 IVIG requests

- **IVIG issues for July 2019 - CWH Site**

There were 16 IVIG issues in July 2019, with 9 new requests

Decision: Approved

- **IVIG issues for July 2019 - WMUH Site**

There were 15 IVIG issues in July 2019, with 6 new requests

Decision: Approved

- **IVIG Issues for August 2019 - CWH Site**

There were 11 IVIG issues in August 2019, with 4 new requests

Decision: Approved

- **IVIG Issues for August 2019 - WMUH Site**

There were 9 IVIG issues in August 2019, with 1 new request

Decision: Approved



- **NHS England: Approval for use for immunoglobulin (Ig) for indications that currently fall into the grey or black categories in Clinical Guidelines for Immunoglobulin use**

Letter from NHS England re Approval for use for immunoglobulin (Ig) for indications that currently fall into the grey or black categories in Clinical Guidelines for Immunoglobulin use

Decision: Noted

- **TMP: Section 27 - Process for demand management of IVIG**

Routine review and update

Updated to include a description of the approval process for IVIg.

Decision: Approved

4.6 Items for noting

- **Quarterly Controlled Drug Summary Report - Q1 2019/20**

Quarterly Controlled Drug Summary report for Q1 2019/20

Decision: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q1 2019/20**

Quarterly CD Accountable Officer report for Q1 2019/20

Decision: Noted

- **Medication Safety Bulletin - Naloxone for opioid Toxicity**

Medication Safety Bulletin re Naloxone for opioid Toxicity

Decision: Noted

- **Medication Safety Bulletin - Prescribing errors and how to prevent**

Medication Safety Bulletin re Prescribing errors and how to prevent

Decision: Noted

- **CCP Report - September**

Clinical Commissioning Report for September

Decision: Noted

- **MHRA Drug Safety Update - July 2019**

MHRA update for June 2019

Decision: Noted

- **MHRA Drug Safety Update - August 2019**

MHRA update for June 2019

Decision: Noted

4.7 Meeting minutes for noting

- **NWLIF meeting - June 2019**

Minutes from NWLIF meeting - June 2019

Decision: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - June 2019**

Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting - July 2019

Decision: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - July 2019**

Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting - July 2019

Decision: Noted

- **Medication Safety Group - July 2019**

Minutes from Medication safety Group meeting - July 2019

Decision: Noted



- **Medication Safety Group - July 2019**

Minutes from Medication safety Group meeting - July 2019

Decision: Noted

4.8 Additional papers to go to Trust Patient Safety Group

- Quarterly Controlled Drug Summary Report - Q1 2019/20
- Quarterly Controlled Drugs Accountable Officer Report - Q1 2019/20

5. Any other business

Nil

6. Date of next meeting

Date: Monday 21st October

Time: 8am-9am

Location: Executive Boardroom and A&E Meeting Room

Closing date: 4th October 2019